全球抗癌藥物市場：重點在於復發性和轉移性領域

專注於復發和轉移性腫瘤藥物的市場規模預計將從 2024 年的 年終的 1,680 億美元，預測期內的複合年成長率為 7.7%。

預計到 2029 年，肺癌藥物市場規模將達到 290 億美元，從 2024 年的 162 億美元成長至 12.4%。預計... 預計到 2029 年，乳癌藥物市場規模將從 2024 年的 137 億美元成長至 236 億美元，複合年成長率為 11.4%。

本報告研究全球癌症治療藥物市場，重點關注復發性和轉移性細分市場，提供市場的全面概述、市場影響因素和市場機會的分析、法律制度、新興技術和技術發展的趨勢、市場規模的趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

目錄

第1章執行摘要

• 市場展望
• 研究範圍
• 市場摘要

第2章 市場概況

• 概述
• 轉移性或復發性癌症的治療類型
• 外科手術
• 化療
• 放射治療
• 標靶治療
• 癌症免疫治療
• 溶瘤病毒治療
• 抗體藥物複合體
• 波特五力分析

第3章 市場動態

• 市場動態
• 市場促進因素
• 抗癌藥順利核准
• 癌症治療的技術進步
• 癌症發生率增加
• 市場限制
• 喪失排他性和普遍性
• 腫瘤科專家短缺
• 市場機會
• 在腫瘤科引入人工智慧
• 前景看好的後期研發藥物

第4章 監管狀況

• 美國核准流程
• FDA 對癌症藥物研發的監管考量
• 歐盟核准流程
• 歐盟核准流程的現狀
• 日本的核准程序

第 5 章新興趨勢與通路分析

• 新興技術
• 個人化癌症疫苗
• 檢測可識別 18 種早期癌症
• CAR-T 細胞療法
• AI
• 降低乳癌風險的藥片
• 奈米粒子
• 腹腔加壓氣霧化療
• 子宮頸癌治療突破
• 新進展
• 生物相似核准
• 管道分析
• 臨床試驗分析
• 專利分析
• 關鍵要點

第6章供應鏈分析

• 概述
• 研究與開發
• 製造業
• 包裝
• 批發商和再包​​裝商
• 藥局
• 消費者分銷
• 抗癌藥物短缺
• 成本
• 製造複雜性
• 地理集中度
• 品質

第7章市場區隔分析

• 細分市場
• 市場分析：按癌症類型
• 肺癌
• 乳癌
• 大腸直腸癌
• 攝護腺癌
• 胃癌
• 肝癌
• 子宮頸癌
• 膀胱癌
• 腎臟癌
• 胰臟癌
• 卵巢癌
• 其他
• 地理分佈
• 市場分析：按地區
• 北美洲
• 歐洲
• 亞太地區
• 其他地區

第8章 競爭訊息

• 概述
• 暢銷抗癌藥物品牌
• 主要企業市場佔有率

第 9 章全球腫瘤藥物市場：重點關注復發和轉移部分 -永續性和 ESG 視角

• ESG 在製藥業中的作用
• ESG績效分析
• 環境因素
• 社會因素
• 管治因素
• ESG風險評估
• 結論

第10章 附錄

• 調查方法
• Start-Ups創企業/顛覆者
• 來源
• 簡稱
• 公司簡介
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.

The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.

The global market for lung cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $16.2 billion in 2024 to reach $29.0 billion by 2029, at a CAGR of 12.4% from 2024 to 2029.

The global market for breast cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $13.7 billion in 2024 to reach $23.6 billion by 2029, at a CAGR of 11.4% from 2024 to 2029.

Report Scope

Both qualitative and quantitative data on the current dynamics impacting the global cancer therapeutics market are presented in this report. It discusses the history of cancer, its different forms, its pathophysiology, its stages of development and its mechanisms of metastasis and recurrence. It also incorporates the disease burden by knowing the epidemiology of different cancers. Treatment patterns that include both non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, cytotoxic/chemotherapy, combinatorial therapy) approaches are discussed to illustrate the various therapeutic options available to patients.

Analyses of the most popular products, the state of clinical trials and new product approvals are also included in the report. The demographics of the major regions-North America, Europe, Asia-Pacific and the Rest of the World-as well as their prospects for growth, are summarized. The profiles of leading companies and the strategies of international businesses involved in the cancer treatment sector are also discussed.

Estimations of the market size for therapies that treat cancer metastases and recurrence states are included in the scope. Cancer types noted in this report include:

• Lung.
• Breast.
• Liver.
• Stomach.
• Prostate.
• Colorectal.
• Gastric.
• Cervical.
• Bladder.
• Kidney.
• Ovarian.
• Lymphoma.
• Multiple myeloma.
• Brain tumors.
• Thyroid.
• Uterine.

Additional growth potential and forecast data are discussed for the cancer therapeutics market, as well as for the cancer types, regions and countries.

For market estimates, data are provided for 2023 as the base year, with forecasts for the period of 2024 through 2029.

Report Includes

• 51 data tables and 83 additional tables
• An overview of the global market for cancer therapeutics with emphasis on recurrent and metastatic divisions
• Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by cancer type and region
• A look at the factors driving the market's growth and constraints
• Insight into the industry value chain analysis, providing a study of the intermediaries involved
• Description of cancer development stages, including the mechanisms of metastasis and recurrences, and the current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns
• Coverage of causes, risk factors, prevalence and incidence of cancer, and information on its economic burden
• Review of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries and radiation
• Identification of the fastest-growing applications and technologies, and a review of current market trends
• Discussion of the industry's ESG challenges and practices
• Review of the current market status, technology issues, industry value chain, Porter's Five Forces, competitive landscape, R&D activity and patent analysis
• Assessment of the vendor landscape, including the market shares of leading companies, their product portfolios and financial overviews
• Updates on recent mergers and acquisitions, facility expansions, collaborations, investments, divestments, new products and other strategic developments
• Profiles of the leading vendors, including Merck & Co. Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Metastatic or Recurrent Cancer Treatment Types
• Surgery
• Chemotherapy
• Radiotherapy
• Targeted Therapy
• Cancer Immunotherapies
• Oncolytic Virotherapy
• Antibody-Drug Conjugates
• Porter's Five Forces Analysis in the Oncology Market
• Potential of New Entrants
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of Substitute Products or Services
• Industry Rivalry: High

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Robust Approval of Oncology Drugs
• Technological Advances in Cancer Treatments
• Increasing Incidence of Cancer Disease
• Market Restraints
• Loss of Exclusivity and Genericization
• Lack of Oncology Professionals
• Market Opportunities
• Incorporation of Artificial Intelligence in Oncology
• Promising Drugs in the Late Stage of the Pipeline

Chapter 4 Regulatory Landscape

• The U.S. Approval Process
• FDA Regulatory Considerations for Oncology Drug Development
• European Union Approval Process
• Current Situation in E.U. Approval Process
• Japanese Approval Process

Chapter 5 Emerging Trends and Pipeline Analysis

• Emerging Technologies
• Personalized Cancer Vaccines
• Test to Identify 18 Early-Stage Cancers
• CAR T-Cell Therapy
• Artificial Intelligence
• Tablet to Cut Breast Cancer Risk
• Nanoparticles
• Pressurized Intraperitoneal Aerosol Chemotherapy
• Cervical Cancer Treatment Breakthrough
• New Developments
• Biosimilar Approvals
• Pipeline Analysis
• Clinical Trial Analysis
• Patent Analysis
• Key Takeaways

Chapter 6 Supply Chain Analysis

• Overview
• Research and Development
• Manufacturing
• Packaging
• Wholesale Distributors and Repackagers
• Pharmacies
• Dispensed to Consumers
• Cancer Drug Shortage
• Costs
• Manufacturing Complexity
• Geographic Concentration
• Quality

Chapter 7 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis, by Cancer Type
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Liver Cancer
• Cervix Cancer
• Bladder Cancer
• Kidney Cancer
• Pancreatic Cancer
• Ovarian Cancer
• All Other Cancers
• Geographic Breakdown
• Market Analysis, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 8 Competitive Intelligence

• Overview
• Blockbuster Oncology Pharmaceutical Brands
• Global Market Shares of Leading Companies

Chapter 9 Sustainability in Cancers Therapeutics Market Emphasis on Recurrent and Metastatic Divisions: ESG Perspective

• Role of ESG in the Pharma Industry
• ESG Performance Analysis
• Environmental Factors
• Social Issues
• Governance Factors
• ESG Risk Ratings
• Conclusion

Chapter 10 Appendix

• Methodology
• Emerging Start-ups/Market Disruptors
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.

List of Tables

• Summary Table : Global Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 1 : Typical Various Metastatic Cancer Treatments
• Table 2 : Promising Drugs in Late Stage of Pipeline, 2023
• Table 3 : FDA Drug Approvals in Oncology, 2021-2023
• Table 4 : Oncology Drug Approvals, 2020-July 2024
• Table 5 : Novel Oncology Drug Approvals for Relapsed or Metastatic Cancers, 2021-November 2024*
• Table 6 : FDA Approved Biosimilar for Oncology Indications, 2015-2024
• Table 7 : FDA Approved Biosimilars and Interchangeable Biosimilars, by FDA, July 2024
• Table 8 : EMA Approved Biosimilar for Oncology Indications, 2007-July 2024
• Table 9 : Clinical Trial Drugs for Metastatic Cancers in Phases 3 and 4, 2024
• Table 10 : Granted Patents in Metastatic Cancer Field, 2022-2024
• Table 11 : Global Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 12 : Clinical Trial Study for Metastatic Lung Cancer, 2024
• Table 13 : Global Market for Lung Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 14 : Common Drugs Used to Treat Metastatic Breast Cancer, 2023
• Table 15 : Clinical Trial Studies for Metastatic Breast Cancer, 2024
• Table 16 : Global Market for Breast Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 17 : Clinical Trial Study for Metastatic Colorectal Cancer, 2024
• Table 18 : Global Market for Colorectal Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 19 : Clinical Trial Study for Metastatic Prostate Cancer, 2024
• Table 20 : Global Market for Prostate Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 21 : Clinical Trial Study for Metastatic Stomach Cancer, 2024
• Table 22 : Global Market for Stomach Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 23 : Clinical Trial Study for Metastatic Liver Cancer, 2024
• Table 24 : Global Market for Liver Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 25 : Clinical Trial Study for Metastatic Cervical Cancer, 2024
• Table 26 : Global Market for Cervical Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 27 : Clinical Trial Study for Metastatic Bladder Cancer, 2024
• Table 28 : Global Market for Bladder Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 29 : Clinical Trial Study for Metastatic Kidney Cancer, 2024
• Table 30 : Global Market for Kidney Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 31 : Clinical Trial Study for Metastatic Pancreatic Cancer, 2024
• Table 32 : Global Market for Pancreatic Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 33 : Clinical Trial Study for Metastatic Ovarian Cancer, 2024
• Table 34 : Global Market for Ovarian Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 35 : Global Market for All Other Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 36 : Global Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
• Table 37 : North American Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 38 : North American Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
• Table 39 : Incidence and Mortality of Cancer Cases in the U.S., Both Sexes, 2024
• Table 40 : U.S. Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 41 : Canadian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 42 : Incidence and Mortality of Cancer Cases in Mexico, Both Sexes, 2022
• Table 43 : Mexican Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 44 : European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 45 : European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
• Table 46 : Incidence and Mortality of Cancer Cases in Germany, Both Sexes, 2022
• Table 47 : German Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 48 : U.K. New Diagnosed Cancer Cases, 2021 and 2022
• Table 49 : U.K. Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 50 : Cancer Incidence and Mortality Cases in Franch, Both Sexes, 2022
• Table 51 : French Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 52 : Cancer Incidence and Mortality Cases in Spain, Both Sexes, 2022
• Table 53 : Spanish Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 54 : Cancer Incidence and Mortality Cases in Italy, Both Sexes, 2022
• Table 55 : Italian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 56 : Rest of the European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 57 : Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 58 : Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
• Table 59 : Cancer Incidence and Mortality in China, Both Sexes, 2022
• Table 60 : Chinese Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 61 : Japanese Cancer Incidence and Mortality, Both Sexes, 2022
• Table 62 : Japanese Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 63 : Cancer Incidence and Mortality Cases in India, Both Sexes, 2022
• Table 64 : Indian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 65 : Cancer Incidence and Mortality Cases in South Korea, Both Sexes, 2022
• Table 66 : South Korean Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 67 : Rest of Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 68 : Rest of World Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
• Table 69 : Drug Pipeline for Major Companies for Metastatic or Relapsed Condition, 2023
• Table 70 : ESG Risk Rankings for Oncology Pharmaceuticals Companies, Through January 2025
• Table 71 : List of a Few Emerging Startups
• Table 72 : Report Information Sources
• Table 73 : Abbreviations Used in the Global Cancer Therapeutics Market with Emphasis on Recurrent and Metastatic Divisions
• Table 74 : AbbVie Inc.: Company Snapshot
• Table 75 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
• Table 76 : AbbVie Inc.: Product Portfolio
• Table 77 : AbbVie Inc.: News/Key Developments, 2023 and 2024
• Table 78 : Amgen Inc.: Company Snapshot
• Table 79 : Amgen Inc.: Financial Performance, FY 2022 and 2023
• Table 80 : Amgen Inc.: Product Portfolio
• Table 81 : Amgen Inc.: News/Key Developments, 2022-2024
• Table 82 : AstraZeneca: Company Snapshot
• Table 83 : AstraZeneca: Financial Performance, FY 2022 and 2023
• Table 84 : AstraZeneca: Product Portfolio
• Table 85 : AstraZeneca: News/Recent Developments, 2022-2024
• Table 86 : Bayer AG: Company Snapshot
• Table 87 : Bayer AG: Financial Performance, FY 2022 and 2023
• Table 88 : Bayer AG: Product Portfolio
• Table 89 : Bayer AG: News/Key Developments, 2023-2024
• Table 90 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 91 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
• Table 92 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 93 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
• Table 94 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 95 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
• Table 96 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 97 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
• Table 98 : Gilead Sciences Inc.: Company Snapshot
• Table 99 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
• Table 100 : Gilead Sciences Inc.: Product Portfolio
• Table 101 : Gilead Sciences Inc.: News/Key Developments, 2022-2024
• Table 102 : Johnson & Johnson Services Inc.: Company Snapshot
• Table 103 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
• Table 104 : Johnson & Johnson Services Inc.: Product Portfolio
• Table 105 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
• Table 106 : Lilly: Company Snapshot
• Table 107 : Lilly: Financial Performance, FY 2022 and 2023
• Table 108 : Lilly: Product Portfolio
• Table 109 : Lilly: News/Key Developments, 2023 and 2024
• Table 110 : Merck & Co. Inc.: Company Snapshot
• Table 111 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
• Table 112 : Merck & Co. Inc.: Product Portfolio
• Table 113 : Merck & Co. Inc.: News/Key Developments, 2021-2024
• Table 114 : Novartis AG: Company Snapshot
• Table 115 : Novartis AG: Financial Performance, FY 2022 and 2023
• Table 116 : Novartis AG: Product Portfolio
• Table 117 : Novartis AG: News/Key Developments, 2022-2024
• Table 118 : Pfizer Inc.: Company Snapshot
• Table 119 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
• Table 120 : Pfizer Inc.: Product Portfolio
• Table 121 : Pfizer Inc.: News/Key Developments, 2021-2024
• Table 122 : Regeneron Pharmaceuticals Inc.: Company Snapshot
• Table 123 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 124 : Regeneron Pharmaceuticals Inc.: Product Portfolio
• Table 125 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
• Table 126 : Sanofi: Company Snapshot
• Table 127 : Sanofi: Financial Performance, FY 2022 and 2023
• Table 128 : Sanofi: Product Portfolio
• Table 129 : Sanofi: News/Key Developments, 2022-2024
• Table 130 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
• Table 131 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 132 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
• Table 133 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2021-2024

List of Figures

• Summary Figure : Global Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, 2023
• Figure 1 : Porter's Five Forces Analysis of the Oncology Market
• Figure 2 : Market Dynamics of the Global Cancer Therapeutics Market Emphasis on Recurrent and Metastatic Divisions
• Figure 3 : Novel Oncology Drugs with FDA Approvals, 2016-2024
• Figure 4 : U.S. Cancer Incidence, 2000-2021
• Figure 5 : Share of Incidence Cases of All Cancer Types, Both Sexes, by WHO Region, 2022
• Figure 6 : Oncology Drug Clinical Trial Studies, by Trial Phase, 2021-July 2024
• Figure 7 : Phase 3 and 4 Clinical Trial Studies of Oncology Drugs for Metastatic and Recurrent Division, by Company, July 2024
• Figure 8 : Top Applicants in Metastatic Cancer Patents, 2022-2024
• Figure 9 : Supply Chain Process of Pharmaceutical Drugs
• Figure 10 : Global Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, 2023
• Figure 11 : Global Market Share of Lung Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 12 : Global Market Share of Breast Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 13 : Global Market Share of Colorectal Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 14 : Global Market Share of Prostate Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 15 : Global Market Share of Stomach Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 16 : Global Market Share of Liver Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 17 : Global Market Share of Cervical Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 18 : Global Market Share of Bladder Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 19 : Global Market Share of Kidney Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 20 : Global Market Share of Pancreatic Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 21 : Global Market Share of Ovarian Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 22 : Global Market Share of All Other Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 23 : Global Market Share of Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
• Figure 24 : North American Market Share of Cancers Therapeutics Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
• Figure 25 : Share of Cancer Incidence Cases in Europe, Both Sexes, by Cancer Type, 2022
• Figure 26 : Share of Cancer Mortality Cases in Europe, Both Sexes, by Cancer Type, 2022
• Figure 27 : European Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
• Figure 28 : U.K. Current and Forecast Cancer Prevalence, 2020-2040
• Figure 29 : Asia-Pacific and Oceania Share of Cancer Incidence, Both Sexes, 2022
• Figure 30 : Asia-Pacific and Oceania Share of Cancer Mortality, Both Sexes, 2022
• Figure 31 : Asia-Pacific Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
• Figure 32 : Top 10 Blockbuster Oncology Pharmaceutical Drugs, by Sales Revenue, 2023
• Figure 33 : Company Share Analysis of Oncology Pharmaceutical Manufacturers, 2023
• Figure 34 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 35 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 36 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 37 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 38 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
• Figure 39 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
• Figure 40 : Bayer AG: Revenue Share, by Business Unit, FY 2023
• Figure 41 : Bayer AG: Revenue Share, by Country/Region, FY 2023
• Figure 42 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
• Figure 43 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
• Figure 44 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 45 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 46 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 47 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 48 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 49 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 50 : Lilly: Revenue Share, by Business Unit, FY 2023
• Figure 51 : Lilly: Revenue Share, by Country/Region, FY 2023
• Figure 52 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 53 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 54 : Novartis AG: Revenue Share, by Business Unit, FY 2023
• Figure 55 : Novartis AG: Revenue Share, by Country/Region, FY 2023
• Figure 56 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 57 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 58 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 59 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 60 : Sanofi: Revenue Share, by Business Unit, FY 2023
• Figure 61 : Sanofi: Revenue Share, by Country/Region, FY 2023
• Figure 62 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 63 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023